Status:
WITHDRAWN
Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
Lead Sponsor:
University Medical Center Groningen
Collaborating Sponsors:
Amsterdam UMC, location VUmc
Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions:
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Molecular imaging can be used for the noninvasive assessment of biodistribution of monoclonal antibodies. Atezolizumab has previously successfully been labeled with the radionucleotide Zirconium-89 (8...
Detailed Description
Patients with a high risk diffuse large B-cell lymphoma (DLBLC) with an international prognostic score (IPI) \> 2, have a high risk of relapse even after achieving a metabolic complete remission with ...
Eligibility Criteria
Inclusion
- Age 18-75 (inclusive) years
- Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) based upon a representative histology specimen according to the World Health Organization (WHO) classification, revision 2016 (see appendix A)
- Ann Arbor stages II-IV (see appendix B)
- WHO performance status 0 - 1 (see appendix E)
- international prognostic index (IPI) ≥ 3 at diagnosis (see appendix C)
- Negative pregnancy test at study entry
- Patient is willing and able use adequate contraception during and until 5 months after the last protocol treatment.
- Written informed consent
- Patient is capable of giving a written informed consent
Exclusion
- Diagnosis
- All histopathological diagnoses other than DLBCL-NOS according to the WHO classification, revision 2016 (see appendix A), including:
- High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations
- Testicular large B-cell lymphoma
- Primary mediastinal B cell lymphoma
- Transformed indolent lymphoma
- Post-transplant lymphoproliferative disorder
- Organ dysfunction
- Clinical signs of severe pulmonary dysfunction
- Clinical signs of heart failure (NYHA classification II-IV)
- Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication.
- Myocardial infarction during the last 6 months
- Significant renal dysfunction (serum creatinine ≥ 150 umol/l or clearance ≤ 30ml/min
- Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula:
- CrCl = (140 - age \[in years\]) x weight \[kg\] (x 0.85 for females) / (0.815 x serum creatinine \[μmol/L\])
- Inadequate hematological function: hemoglobin \< 5.5 mmol/L,absolute neutrophil count (ANC) \< 1.0x10\^9/L or platelets \< 75x10\^9 /L
- Spontaneous international normalized ratio (INR) \> 1.5, activated partial thromboplastin time (aPTT) \>33
- Significant hepatic dysfunction (total bilirubin ≥ 1.5x upper limit of normal (ULN) or transaminases ≥ 2.5 x ULN), unless related to Gilberts syndrome.
- Clinical signs of severe cerebral dysfunction
- Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- Major surgery within the last 4 weeks
- Known or suspected infection
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks before date of registration. Suspected active or latent tuberculosis needs to be confirmed by positive interferon gamma (IFN-γ) release assay
- Patients known to be human immunodeficiency virus (HIV)-positive
- Active chronic hepatitis B or C infection
- Administration of a live, attenuated vaccine within 4 weeks before date of registration or anticipation that such a live attenuated vaccine will be required during the study and for a period of 5 months after discontinuation of atezolizumab
- Auto-immune
- Any active or history of documented autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following exceptions are allowed: Patients with autoimmune-related hypothyroidism or type 1 diabetes mellitus who are on stable treatment.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest CT scan at screening.
- Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment
- Regular treatment with corticosteroids within the 4 weeks prior to date of registration, unless administered for indications other than non-Hodgkin lymphoma (NHL) at a dose equivalent to \< 30 mg/day prednisone/prednisolone.
- General
- Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease)
- Current participation in another clinical trial interfering with this trial
- History of active cancer during the past 5 years, except basal cell carcinoma of the skin or stage 0 cervical carcinoma
- Life expectancy \< 6 months
- Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Prior treatment
- Prior treatment with atezolizumab, or anti PD1 or PDL1 antibodies.
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) therapeutic antibodies.
- Treatment with systemic immunostimulatory agents (including but not limited to interferon (IFN), interleukin (IL)-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to date of registration.
- Treatment with systemic immunosuppressive medications, including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti- tumor necrosis factor (anti-TNF) agents within 2 weeks prior to date of registration; inhaled corticosteroids and mineralocorticoids are allowed.
Key Trial Info
Start Date :
May 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03850028
Start Date
May 22 2019
End Date
May 1 2022
Last Update
May 15 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
VU University Medical Center
Amsterdam, North Holland, Netherlands, 1081HV
2
University Medical Center Groningen
Groningen, Netherlands, 9100 RB